Prevention of osteoporosis and uterine effects in post-menopausal women taking raloxifene for 5 years.
Api
Murat
M
D015519:Bone Density / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000517:prevention & control; D016009:Chi-Square Distribution; D016001:Confidence Intervals; D004965:Estrogen Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008159:Lumbar Vertebrae / Q000502:physiology; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D020849:Raloxifene Hydrochloride / Q000494:pharmacology* / Q000627:therapeutic use; D015203:Reproducibility of Results; D014599:Uterus / Q000187:drug effects
D004965:Estrogen Antagonists; D020849:Raloxifene Hydrochloride